News
TWST
111.91
-8.72%
-10.69
Alger Mid Cap 40 ETF Q3 2026 Portfolio Review
Seeking Alpha · 1h ago
Twist Bioscience Shares Down On Soft Forecast
Dow Jones · 1h ago
Midday Fly By: Nvidia CEO resigns, Hancock Whitney acquires Trustmark
TipRanks · 2h ago
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Benzinga · 2h ago
Twist Bioscience Stock Gets A New MRD Testing Launch With Faster Custom Panels
Simply Wall St · 5h ago
Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
Seeking Alpha · 5h ago
Twist Bioscience Q4 2026 Earnings Call Transcript
Benzinga · 5h ago
Twist Bioscience sees FY27 revenue $550M-$560M, consensus $548.67M
TipRanks · 6h ago
Twist Bioscience sees Q1 revenue $130M-$132M, consensus $126.42M
TipRanks · 6h ago
Twist Bioscience reports Q4 EPS (32c), consensus (20c)
TipRanks · 7h ago
Twist Bioscience Q4 EPS $(0.32) Beats $(0.34) Estimate, Sales $126.644M Beat $123.085M Estimate
Benzinga · 7h ago
Twist Bioscience beats top-line and bottom-line estimates; gives Q1 and FY2027 outlook
Seeking Alpha · 7h ago
*Twist Bioscience Sees FY27 Rev $550M-$560M >TWST
Dow Jones · 7h ago
*Twist Bioscience Sees 1Q Rev $130M-$132M >TWST
Dow Jones · 7h ago
Twist Bioscience Sees FY2027 Sales $550.000M-$560.000M vs $547.137M Est
Benzinga · 7h ago
Twist Bioscience Sees Q1 Sales $130.000M-$132.000M vs $126.354M Est
Benzinga · 7h ago
*Twist Bioscience 4Q Loss/Shr 32c >TWST
Dow Jones · 7h ago
*Twist Bioscience 4Q Rev $126.6M >TWST
Dow Jones · 7h ago
Press Release: Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
Dow Jones · 7h ago
U.S. Earnings Preview: Before Market Open Nov. 12
Dow Jones · 8h ago
More
Webull provides a variety of real-time TWST stock news. You can receive the latest news about Twist Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About TWST
Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.